KIRKLAND, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported financial results for the first quarter fiscal 2026, which ended July 31, 2025. Financial HighlightsGenerated revenue of $19.4 million in Q1 FY26, an increase of 52% compared to the prior year period. Expanded gross margin to 45.7% in Q1 FY26 compared to 32.9% in the prior year period. Increased FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25.“We had a strong start to fiscal 2026, with our sustained commercial momentum generating revenue growth of over 50% in the first quarter,” said Brian Webster, President and CEO. “We also continued to make progress on several key operational objectives, including growing the commercial...

Press Release VRANKEN-POMMERY MONOPOLE AVAILABILITY OF THE 2025 HALF-YEAR FINANCIAL REPORT Reims, September 11th 2025 VRANKEN-POMMERY MONOPOLE Group has filed today its 2025 half-year Financial Report with the French Autorité des Marchés Financiers (AMF). It is available to the public under the conditions set out in the regulations in force and can be downloaded from the Group’s website in the Investor Relations / Press Releases and Regulated Information section at the following address: https://www.vrankenpommery.com/finance/communiques-et-information-reglementee About Vranken-Pommery Monopole Vranken-Pommery Monopole is a leading wine player in Europe and the second largest champagne group.The group manages 2,600 hectares of land, owned outright or under lease and spread over four vineyards in Champagne, Provence, Camargue and...

FINANCIAL PRESS RELEASE FIRST-HALF 2025 RESULTS A performance that translates into a slight improvement in net incomeConsolidated revenue stable at €109.3m (-0.2%) +€0.5m increase in Group net incomeReims, September 11, 2025The Board of Directors of Vranken-Pommery Monopole met on September 11, 2025 under the chairmanship of Mrs. Nathalie Vranken, and in the presence of the Statutory Auditors, to approve the Group’s financial statements for the half year 2025.The limited review procedures on the half-year financial statements have been performed by the Statutory Auditors, their report is being issued.Consolidated dataH1 2025 (€m) H1 2024 (€m) Var vs H1 24 (€m) Var vs H1 24 (%)Turnover 109.3 109.6 -0.2 -0.2%Recurring operating income 13.8 15.1 -1.2 -8.0%Operating income 13.7 14.7 -1.1 -7.2%Financial result -15.3 -16.4 +1.0  ...

FORT WAYNE, Ind., Sept. 11, 2025 (GLOBE NEWSWIRE) — Vera Bradley, Inc. (Nasdaq: VRA) (the “Company”) today announced its financial results for the second quarter of the fiscal year ending January 31, 2026 (“Fiscal 2026”). Second Quarter Comments “Our second quarter results were in line with our internal expectations. Notably we saw sequential improvement versus the first quarter in comparable store sales across our store fleet and on VB.com, and in each month during the second quarter. We are encouraged that this trend has continued and that our brand channels are leading the way.” said Ian Bickley, Executive Chairman of Vera Bradley. Bickley continued, “We are in the early stages of making meaningful adjustments to our product design and assortment, driving innovation back into our core DNA and what made Vera Bradley successful....

Q2 FY26 Net Sales Increased 2.5% to $160.5 Million vs. Q2 FY25 STAMFORD, Conn., Sept. 11, 2025 (GLOBE NEWSWIRE) — The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand best known for its Sactionals, The World’s Most Adaptable Couch, today announced financial results for the second quarter of fiscal 2026, which ended August 3, 2025. Shawn Nelson, Chief Executive Officer, stated, “We’re pleased to have delivered another quarter of market share gains underpinned by our secular growth initiatives across Designed for Life product platforms and efficient customer acquisition engines. Our operational discipline continues to drive operating expense leverage even as we maintain an investment stance for innovation and long-term growth. Our financial and operational performance,...

Successful Canadian Distribution Transition Puts GURU Back in Direct Relationship with its Customers, Driving Flexibility, Growth and Strong Earnings Key Highlights:First profitable quarter since becoming public in 2020, with net income of $1.3 million in Q3 versus a $2.2 million loss in Q3 2024; year-to-date net loss decreased 79% to $1.4 million. Record net revenue of $10.4 million in Q3, up 31.4% from $7.9 million in Q3 2024. Gross margin expanded to 71.3% in Q3, including a one-time change in estimate related to the termination of the Canadian exclusive distribution agreement. Excluding this adjustment, gross margin was 65.9%, compared to 55.4% last year. Continued strong financial position with $24.2 million in cash, cash equivalents and short-term investments, no debt, and $10 million of unused credit facilities as of July 31,...

Company reaffirms dividend, maintains profitability focus, and positions for growth MARTINSVILLE, Va., Sept. 11, 2025 (GLOBE NEWSWIRE) — Hooker Furnishings Corporation (NASDAQ-GS: HOFT) (“Hooker” or the “Company”), a global leader in home furnishings, today reported operating results for its fiscal 2026 second quarter ended August 3, 2025. Executive Commentary “Hooker Furnishings is taking decisive steps to return the business to profitability. Our cost-reduction initiatives and focus on growth initiatives have positioned the Company to maintain resilience in today’s challenging environment, and to strategically capture growth when demand returns,” said Jeremy Hoff, Chief Executive Officer. “Hooker Branded broke even in the quarter despite weak demand and $655,000 in restructuring charges, and Domestic Upholstery reduced its operating...

NOTTINGHAM, United Kingdom, Sept. 11, 2025 (GLOBE NEWSWIRE) — Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, today announces a business update and provides its final audited financial results for the year ended 30 April 2025. Key highlights (including post-period) DNA ImmunoBody® SCIB1/iSCIB1+ (SCOPE trial)Positive data reported from Phase 2 SCOPE trial shows iSCIB1+ in combination with checkpoint inhibitors has the potential to set the new standard for advanced melanomaProgression-free survival (PFS) for iSCIB1+ in the target HLA population at 11 months is 78% comparing favourably against historic 12 month PFS of 46% reported by doublet checkpoint therapy of ipilimumab and nivolumab 1Combined data for the defined human leukocyte antigen (HLA) target...

TORONTO, Sept. 10, 2025 (GLOBE NEWSWIRE) — Currency Exchange International, Corp. (the “Group” or “CXI”) (TSX: CXI; OTCQX: CURN), today reported net income of $4.2 million for the third quarter of 2025, 8% higher than the prior year (all figures are in U.S. dollars except where otherwise indicated). This 2025 reported net income reflected $5.2 million net income from continuing operations and a net loss of $1.0 million from Exchange Bank of Canada, the Company’s Canadian subsidiary which was classified as discontinued operations effective the second quarter of 2025. These third quarter results included a net restructuring credit of $0.1 million related to discontinued operations in Canada. Excluding restructuring amounts, the Group’s adjusted net income1 decreased by 10% compared to the prior year and adjusted diluted earnings...

JOHANNESBURG, Sept. 10, 2025 (GLOBE NEWSWIRE) — Lesaka Technologies, Inc. (Nasdaq: LSAK; JSE: LSK) today released preliminary unaudited results for the fourth quarter (“Q4 2025”) and full year of fiscal 2025 (“FY2025”). FY2025 performance:All growth rates are year-on-year between FY2025 and FY2024.Net Revenue (a non-GAAP measure) of $328.7 million (ZAR 5.3 billion), up 38% in ZAR. Net Loss of $87.5 million (ZAR 1.6 billion), up 386% in ZAR largely due to inclusion of a tax adjusted $49.3 million (ZAR 897.6 million) non-operating, non-cash charge relating to a change in fair value and sale of MobiKwik (a non-core asset), a tax adjusted non-cash charge from impairment losses of $18.4 million (ZAR 326.2 million) and once-off transaction costs of $17.8 million (ZAR 321.9 million). Group Adjusted EBITDA (a non-GAAP measure) of $50.7...